News and Announcements
Imugene Announces New Strategic Partnership with the Baker Institute
- Published February 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX:IMU) incurred expenditure of $2.27m, which was offset in large part by an expected rebate of $0.77m under the Australian Governments R&D tax incentive scheme. The majority of expense, being $1.65m, were incurred on research and development, with the balance being payroll and administration costs.
KEY TAKEAWAYS:
- New strategic partnerships with the Baker Institute investigating the opportunities for small molecules in immune-oncology.
- Four new mimotope patents filed to expand Imugene pipeline into B-cell vaccine compositions and franchise.
- Successful $3.2M private placement with sophisticated and institutional investors.
- Cash and cash equivalents 31 December 2016: Up 41% on pcp to $3.8M.
- Phase 1b/2 trial in patients with metastatic gastric cancer to recruit in 2017.
- Loss for the 6 months to 31 December 2016: Up 45.00% on previous comparable period (‘pcp’) to $1.49M.
Imugene is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
